-The first therapeutic equivalent to Lo/Ovral®*†1
  • Pharmacokinetic studies demonstrate bioequivalence1
-Appropriate for many oral contraceptive users
  • Contains 30 mcg ethinyl estradiol
  • Suitable for many first-time OC users
-Competitively priced to Lo/Ovral®*
-Easy-to-use 28-day regimen

SAFETY INFORMATION
Women who use oral contraceptives (OCs) should be strongly advised not to smoke due to the increased risk of cardiovascular side effects. Serious risks reported with the use of OCs include blood clots, stroke, and heart attacks. OCs are contraindicated in women with thrombophlebitis, thromboembolic disorders, breast cancer, hepatic or estrogen-dependent neoplasia, cerebrovascular or coronary artery disease, jaundice, or undiagnosed genital bleeding. OCs do not protect against HIV infection (AIDS) or other sexually transmitted diseases.

Please see full Prescribing Information.
*Lo/Ovral is a registered trademark of Wyeth-Ayerst Laboratories.
†Based on an open-label, single-dose, two-treatment, two-sequence crossover study.
Reference: 1. Data on file, Watson Pharma, Inc.



Watson Pharmaceuticals, Inc.
Site Last Updated: 2006-06-23
This site is intended for US residents only. Copyright © 2003 - 2008 Watson Pharma, Inc. All rights reserved.
Terms of Use
Legal/Copyright Disclaimer Privacy Policy